Site is Being Upgraded

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Triiodothyronine, a thyroid hormone (T3),  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 30/January/2017, 11.41 pm

Molecular therapy for anxiety and depression: Sertraline (Brand name: Zoloft, Lustral) decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 30/January/2018, 11.33 pm
January 30, 2018
Antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: 9-Aminoacridine increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via up regulation of its target gene, 31/January/2018, 11.13 pm
January 31, 2018
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a thyroid hormone-based therapy for NAFLD. Triiodothyronine, by increasing the expression of its target gene, it may (1) promote degradation of HMGCR; and (2) suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing Triiodothyronine or its analogues, either alone or in combination with other drugs” may be used to treat NAFLD.

[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how Triiodothyronine decreases the expression of HMGCR to prevent progression to NAFLD.

Figure 2. The chemical structure of Triiodothyronine.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Triiodothyronine decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Triiodothyronine, a thyroid hormone (T3),  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 30/January/2017, 11.41 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.